Abstract:ABSTRACT Accurate and timely diagnosis of severe acute respiratory syndrome coronavirus (SARS-CoV) infection is a critical step in preventing another global outbreak. In this study, 829 serum specimens were collected from 643 patients initially reported to be infected with SARS-CoV. The sera were tested for the N protein of SARS-CoV by using an antigen capture enzyme-linked immunosorbent assay (ELISA) based on monoclonal antibodies against the N protein of SARS-CoV and compared to 197 control serum samples from healthy donors and non-SARS febrile patients. The results of the N protein detection analysis were directly related to the serological analysis data. From 27 SARS patients who tested positive with the neutralization test, 100% of the 24 sera collected from 1 to 10 days after the onset of symptoms were positive for the N protein. N protein was not detected beyond day 11 in this group. The positive rates of N protein for sera collected at 1 to 5, 6 to 10, 11 to 15, and 16 to 20 days after the onset of symptoms for 414 samples from 298 serologically confirmed patients were 92.9, 69.8, 36.4, and 21.1%, respectively. For 294 sera from 248 serological test-negative patients, the rates were 25.6, 16.7, 9.3, and 0%, respectively. The N protein was not detected in 66 patients with cases of what was initially suspected to be SARS but serologically proven to be negative for SARS and in 197 serum samples from healthy donors and non-SARS febrile patients. The specificity of the assay was 100%. Furthermore, of 16 sera collected from four patients during the SARS recurrence in Guangzhou, 5 sera collected from 7 to 9 days after the onset of symptoms were positive for the N protein. N protein detection exhibited a high positive rate, 96 to 100%, between day 3 and day 5 after the onset of symptoms for 27 neutralization test-positive SARS patients and 298 serologically confirmed patients. The N protein detection rate continually decreased beginning with day 10, and N protein was not detected beyond day 19 after the onset of symptoms. In conclusion, an antigen capture ELISA reveals a high N protein detection rate in acute-phase sera of patients with SARS, which makes it useful for early diagnosis of SARS.

Profiles Of Igg Antibodies To Nucleocapsid And Spike Proteins Of The Sars-Associated Coronavirus In Sars Patients

Comparison of Immunoglobulin G Responses to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS.

Antibody responses to individual proteins of SARS coronavirus and their neutralization activities.

Profiles Of Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus Recombinant Proteins And Their Potential Use As Diagnostic Markers

Clinical Application Study on SARS-CoV Spike Protein Antigenic Specificity

Human Post‐infection Serological Response to the Spike and Nucleocapsid Proteins of SARS‐CoV‐2

Development and Evaluation of an Enzyme-Linked Immunosorbent Assay for Detection of Antibodies Against the Spike Protein of Sars-Coronavirus

[A Follow Up Study of Total IgM, IgG, Nucleoprotein and Spike Protein Antibodies Against Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS].

Reactivity of Antigens Derived from Different Structural Genes of SARS-CoV to Convalescent Sera

Monoclonal Antibody-Based Antigen Capture Enzyme-Linked Immunosorbent Assay Reveals High Sensitivity of the Nucleocapsid Protein in Acute-Phase Sera of Severe Acute Respiratory Syndrome Patients.

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients.

Cloning, Expression, Purification of a Fusion Protein of SARS-CoV Nucleocapsid and Spike Protein Fragments and Its Immunological Characteristics

The Epitope Study on the SARS-CoV Nucleocapsid Protein

Longitudinal Profile of Antibodies Against Sars-Coronavirus in Sars Patients and Their Clinical Significance

Detection of Antibodies Against SARS-CoV in Serum from SARS-infected Donors with ELISA and Western Blot

IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients

Antigenicity Analysis of Different Regions of the Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein

Identification of Epitopes on SARS-CoV Nucleocapsid Protein That Induce the Cross-or Specific-Reactivity among SARS-CoV,HCoV-OC43 and HCoV-229E

Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection.

Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.

Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years after Recovery from SARS.